Expert Opinion on Investigational Drugs, Volume 26, Issue 8 (2017)

Browse this journal
Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days

Expert Opinion on Investigational Drugs, Volume 26, Issue 8 (2017)

See all volumes and issues
Vol 33, 2024 Vol 32, 2023 Vol 31, 2022 Vol 30, 2021 Vol 29, 2020 Vol 28, 2019 Vol 27, 2018 Volume 26, 2017 Vol 25, 2016 Vol 24, 2015 Vol 23, 2014 Vol 22, 2013 Vol 21, 2012 Vol 20, 2011 Vol 19, 2010 Vol 18, 2009 Vol 17, 2008 Vol 16, 2007 Vol 15, 2006 Vol 14, 2005 Vol 13, 2004 Vol 12, 2003 Vol 11, 2002 Vol 10, 2001 Vol 9, 2000 Vol 8, 1999 Vol 7, 1998 Vol 6, 1997 Vol 5, 1996 Vol 4, 1995 Vol 3, 1994
Download citations Download PDFs Download issue

Editorial

Editorial
Do STAT3 inhibitors have potential in the future for cancer therapy?
Andrea L.A. Wong, Jayshree L. Hirpara, Shazib Pervaiz, Jie-Qing Eu, Gautam Sethi & Boon-Cher Goh
Pages: 883-887
Published online: 17 Jul 2017
First Page PreviewforDo STAT3 inhibitors have potential in the future for cancer therapy? | Full Text | References | PDF (500.5 KB)
  • 16065 Views
  • 177 CrossRef citations
  • 0Altmetric
Free Access

Original Research

Article
A randomized, single-blind, Phase I trial (INVICTAN-1) assessing the bioequivalence and safety of BI 695502, a bevacizumab biosimilar candidate, in healthy subjects
Willem Hettema, Christopher Wynne, Benjamin Lang, Mario Altendorfer, Niklas Czeloth, Ragna Lohmann, Sandeep Athalye & Dorothee Schliephake
Pages: 889-896
Published online: 12 Jul 2017
AbstractforA randomized, single-blind, Phase I trial (INVICTAN-1) assessing the bioequivalence and safety of BI 695502, a bevacizumab biosimilar candidate, in healthy subjects | Full Text | References | PDF (1.2 MB)
  • 2874 Views
  • 24 CrossRef citations
  • 0Altmetric
Free Access

Review

Review
Investigational antiarrhythmic agents: promising drugs in early clinical development
Jordi Heijman, Shokoufeh Ghezelbash & Dobromir Dobrev
Pages: 897-907
Published online: 20 Jul 2017
AbstractforInvestigational antiarrhythmic agents: promising drugs in early clinical development | Full Text | References | PDF (1 MB)
  • 605 Views
  • 30 CrossRef citations
  • 0Altmetric
Review
Bruton’s tyrosine kinase inhibitors in B-cell lymphoma: current experience and future perspectives
T. Seiler & M. Dreyling
Pages: 909-915
Published online: 10 Jul 2017
AbstractforBruton’s tyrosine kinase inhibitors in B-cell lymphoma: current experience and future perspectives | Full Text | References | PDF (736.7 KB)
  • 1011 Views
  • 26 CrossRef citations
  • 0Altmetric
Review
Experimental and early investigational drugs for androgenetic alopecia
Hongwei Guo, Wendi Victor Gao, Hiromi Endo & Kevin John McElwee
Pages: 917-932
Published online: 12 Jul 2017
AbstractforExperimental and early investigational drugs for androgenetic alopecia | Full Text | References | PDF (1.3 MB)
  • 1010 Views
  • 12 CrossRef citations
  • 0Altmetric
Review
Promising investigational drug candidates in phase I and phase II clinical trials for mesothelioma
Alice Guazzelli, Emyr Bakker, Kun Tian, Constantinos Demonacos, Marija Krstic-Demonacos & Luciano Mutti
Pages: 933-944
Published online: 12 Jul 2017
AbstractforPromising investigational drug candidates in phase I and phase II clinical trials for mesothelioma | Full Text | References | PDF (1.2 MB)
  • 327 Views
  • 11 CrossRef citations
  • 0Altmetric
Review
Investigational drugs in development for focal segmental glomerulosclerosis
Howard Trachtman
Pages: 945-952
Published online: 14 Jul 2017
AbstractforInvestigational drugs in development for focal segmental glomerulosclerosis | Full Text | References | PDF (651.5 KB)
  • 477 Views
  • 2 CrossRef citations
  • 0Altmetric
Review
Investigational therapies for the treatment of narcolepsy
Stefano de Biase, Annacarmen Nilo, Gian Luigi Gigli & Mariarosaria Valente
Pages: 953-963
Published online: 20 Jul 2017
AbstractforInvestigational therapies for the treatment of narcolepsy | Full Text | References | PDF (788.7 KB)
  • 548 Views
  • 4 CrossRef citations
  • 0Altmetric

Drug Evaluation

Article
Entinostat for the treatment of breast cancer
Dario Trapani, Angela Esposito, Carmen Criscitiello, Luca Mazzarella, Marzia Locatelli, Ida Minchella, Saverio Minucci & Giuseppe Curigliano
Pages: 965-971
Published online: 24 Jul 2017
AbstractforEntinostat for the treatment of breast cancer | Full Text | References | PDF (638.8 KB)
  • 702 Views
  • 46 CrossRef citations
  • 0Altmetric
Article
Selumetinib for the treatment of non-small cell lung cancer
Francesca Casaluce, Assunta Sgambato, Paolo Maione, Paola Claudia Sacco, Giuseppe Santabarbara & Cesare Gridelli
Pages: 973-984
Published online: 12 Jul 2017
AbstractforSelumetinib for the treatment of non-small cell lung cancer | Full Text | References | PDF (857.3 KB)
  • 446 Views
  • 23 CrossRef citations
  • 0Altmetric
Article
Lurasidone for the treatment of irritability and anger in autism spectrum disorders
Lynn McClellan, Kelli C. Dominick, Ernest V. Pedapati, Logan K. Wink & Craig A. Erickson
Pages: 985-989
Published online: 24 Jul 2017
AbstractforLurasidone for the treatment of irritability and anger in autism spectrum disorders | Full Text | References | PDF (408.9 KB)
  • 980 Views
  • 13 CrossRef citations
  • 0Altmetric
Article
Alicaforsen for the treatment of inflammatory bowel disease
Vipul Jairath, Reena Khanna & Brian G. Feagan
Pages: 991-997
Published online: 06 Jul 2017
AbstractforAlicaforsen for the treatment of inflammatory bowel disease | Full Text | References | PDF (573 KB)
  • 559 Views
  • 22 CrossRef citations
  • 0Altmetric

Explore articles